- Home
- OTLK
OTLK
Outlook Therapeutics Inc.
as 04-18-2025 1:41pm EST
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | ISELIN |
| Market Cap: | N/A | IPO Year: | 2016 |
| Target Price: | $10.20 | AVG Volume (30 days): | 448.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.19 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.87 - $9.29 | Next Earning Date: | 05-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 288.46% |
Latest Outlook Therapeutics Inc. News
OTLK Breaking Stock News: Dive into OTLK Ticker-Specific Updates for Smart Investing
MT Newswires
11 days ago
Outlook Therapeutics Says FDA Accepts Biologics License Application for Wet AMD Treatment
GlobeNewswire
11 days ago
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
GlobeNewswire
2 months ago
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration
GlobeNewswire
2 months ago
Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
GlobeNewswire
2 months ago
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update
GlobeNewswire
2 months ago
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment
GlobeNewswire
3 months ago
Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors
GlobeNewswire
3 months ago
Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD
Compare OTLK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OTLK Outlook Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.